- Conditions
- HIV Infections, Non-Alcoholic Fatty Liver Disease
- Interventions
- Semaglutide
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Aurora, Colorado • Baltimore, Maryland + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 300
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Autism Spectrum Disorder, Obesity
- Interventions
- Glucagon-like peptide-1 receptor agonist：Semaglutide, Lifestyle Management (LSM) Counseling
- Drug · Behavioral
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 12 Years to 18 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Obesity, Childhood
- Interventions
- Intensive Behavioral Program, Semaglutide and Behavioral Program
- Behavioral · Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- NAFLD
- Interventions
- Semaglutide Pen Injector, Placebo
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Overweight, Obesity
- Interventions
- Semaglutide, Placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Escondido, California • Huntington Park, California + 13 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Dulaglutide Pen, Semaglutide Pen
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 312 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 14
- States / cities
- Fresno, California • Long Beach, California • Palm Harbor, Florida + 10 more
- Conditions
- Bipolar I Disorder, Bipolar II Disorder, Schizo Affective Disorder, Obesity, Weight Loss, GLP - 1
- Interventions
- Group Therapy Program, semaglutide, Phentermine-Topiramate, naltrexone and bupropion (combination)
- Behavioral · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Overweight, Obesity
- Interventions
- NNC0721-8060, Semaglutide, Placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 142 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- Lenexa, Kansas • San Antonio, Texas
- Conditions
- Adults With Overweight/Obesity and Type 2 Diabetes
- Interventions
- AT673 low dose, AT673 high dose, Placebo
- Drug
- Lead sponsor
- Antag Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 8
- States / cities
- Chandler, Arizona • Anaheim, California • Hollywood, Florida + 5 more
- Conditions
- Obesity
- Interventions
- TAP® Micro Select Device (Touch Activated Phlebotomy)
- Device
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Medford, Massachusetts
- Conditions
- Diabetes
- Interventions
- Semaglutide, DPP-4 inhibitor
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 742,670 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Obesity
- Interventions
- Semaglutide 2.4 mg and NNC0165-1875 2.0 mg, Semaglutide 2.4 mg and placebo 2.0 mg, Semaglutide 2.4 mg and NNC0165-1875 1.0 mg, Semaglutide 2.4 mg and placebo 1.0 mg
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Anaheim, California • Chula Vista, California + 22 more
- Conditions
- Obesity, Body Weight Changes
- Interventions
- Voice data
- Behavioral
- Lead sponsor
- Loma Linda University
- Other
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 59 participants
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Loma Linda, California
- Conditions
- Alcohol Use Disorder (AUD), Obesity (BMI Equal to or >30)
- Interventions
- Placebo, Semaglutide 1.0 mg, Semaglutide 2.0 mg
- Other · Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 68 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Semaglutide, Placebos
- Drug
- Lead sponsor
- Sabyasachi Sen
- Other
- Eligibility
- 20 Years to 90 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Alzheimer Dementia (AD)
- Interventions
- IL-2 (Aldesleukin), Semaglutide Plus IL-2, Placebo
- Drug
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 50 Years to 86 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Obesity
- Interventions
- Incretin-based therapies (GLP-1 and GLP-1/GIP)
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 125,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Type 2 Diabetes
- Interventions
- Tirzepatide, Dulaglutide, Semaglutide
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 70,000 participants
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Type 2 Diabetes, End Stage Renal Disease on Dialysis
- Interventions
- Semaglutide, Placebo
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 5
- States / cities
- Chapel Hill, North Carolina • Dallas, Texas • Irving, Texas
- Conditions
- Obesity
- Interventions
- Semaglutide, Placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 6 Years to 18 Years
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 24
- States / cities
- Escondido, California • New Haven, Connecticut • Columbus, Georgia + 19 more
- Conditions
- Obesity/Therapy
- Interventions
- Semaglutide 1.7mg subcutaneous, Placebo
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 12 Years to 45 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Obesity and Overweight
- Interventions
- NNC0165-1875, Placebo (NNC0165-1875), Semaglutide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- Male only
- Enrollment
- 88 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Obesity & Overweight
- Interventions
- Semaglutide 6 mg liquid emulsion formulation, Wegovy® (semaglutide) Tablet, Placebo liquid emulsion formulation
- Drug
- Lead sponsor
- Gila Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Obesity, Type 2 Diabetes
- Interventions
- Cagrisema, Semaglutide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 99
- States / cities
- Birmingham, Alabama • Pelham, Alabama • Gilbert, Arizona + 81 more